Cervical cancer jab “in a year”BMJ 2005; 331 doi: https://doi.org/10.1136/bmj.331.7521.864-a (Published 13 October 2005) Cite this as: BMJ 2005;331:864
- Susan Mayor
A vaccine against human papillomavirus (HPV) strains that cause most cervical cancers has been shown to be highly effective, a study reported last week.
The two year study found that a quadrivalent recombinant vaccine against HPV types 6, 11, 16, 18 was 100% effective in preventing early stage cancers and precancerous abnormalities caused by the two key strains of HPV—16 and 18—that are associated with 70% of cervical cancers. This is the finding of a phase III study reported at the annual meeting of the Infectious Diseases Society of America.
The study, called FUTURE II, randomised 12 167 women aged 16 to 26 years from 13 countries to a three-dose regimen of …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial